Company news
OS Therapies Incorporated news in 2025
OS Therapies Incorporated's news releases, calls and decks from 2025, newest first.
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
December 15, 2025
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
December 9, 2025
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
December 5, 2025
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
November 25, 2025
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
November 20, 2025
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
November 17, 2025
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
October 22, 2025
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
October 17, 2025
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
October 10, 2025
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
October 9, 2025
OS Therapies to Participate in Fall 2025 Conferences and Events
October 7, 2025
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
September 30, 2025
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11: 00am EDT
September 19, 2025
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
September 12, 2025
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
September 3, 2025
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting
September 2, 2025
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
September 2, 2025
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
August 27, 2025
OS Therapies Terminates Equity Line of Credit
August 25, 2025
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
August 19, 2025
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
August 14, 2025
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
August 7, 2025
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
August 7, 2025
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
July 14, 2025
OS Therapies Provides Clinical & Global Regulatory Updates
July 10, 2025
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
July 3, 2025
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
June 30, 2025
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
June 24, 2025
OS Therapies Announces Warrant Exercise Inducement & Exchange Offer
June 23, 2025
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
June 10, 2025
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
June 6, 2025
OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
May 16, 2025
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
May 15, 2025
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
May 7, 2025
OS Therapies FDA Meeting Request Granted
April 22, 2025
Decks in 2025
- Investor Presentation (October 2025)
Investor deck · 28 slides · Oct 17, 2025